RxDoctor Payments Data

Daniel Obermark

Optometrist · Sikeston, MONPI 1194709220

Payments from drug & device makers

$1,248in general payments, 2019–2025

Across 42 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$301
  • Bausch & Lomb Americas Inc.$268
  • Carl Zeiss Meditec, Inc.$240
  • Alcon$189
  • Novartis$144
  • Oyster Point Pharma, Inc.$44
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$1,00881%
  • Other$24019%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,248 in reported general payments places this provider in the 60th percentile of 1,030 optometrist providers in Missouri.

See all optometrist providers in Missouri

Medicare billing

Part B allowed, 2024
$36,220
Medicare patients
210
Services billed
452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine156$159,328
LumiganBimatoprost226$103,080
XiidraLifitegrast68$92,684
CombiganBrimonidine Tartrate/Timolol43$21,181
MieboPerfluorohexyloctane/Pf27$20,475
Cyclosporine24$15,854
Alphagan PBrimonidine Tartrate32$11,145
SimbrinzaBrinzolamide/Brimonidine Tart34$8,288
AzoptBrinzolamide12$7,192
Loteprednol Etabonate23$3,449
Latanoprost233$2,296
Brinzolamide12$1,911
Tobramycin-DexamethasoneTobramycin/Dexamethasone30$1,810
Fluorometholone23$1,343
Brimonidine Tartrate59$1,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$301$294,735457 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$268$113,15995 claims
AlconSimbrinza, Azopt$189$15,48046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,030 optometrist providers in Missouri.

Other optometrist in Sikeston

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →